Article Type
Plain Language Summary
Published
Background About 2 out of 3 individuals who present to a doctor with symptoms of small cell lung cancer (SCLC) will be diagnosed with advanced disease. Standard treatment with platinum-etoposide plus atezolizumab or durvalumab is highly effective; however, virtually all patients who respond to this primary (first-line) treatment will become resistant to platinum and relapse. […]